The ideal candidate for this project will be highly motivated and passionate about translating basic scientific observations into a preclinical, and ultimately a clinical setting. Previous experience in cell culture, small animal handling and imaging are desirable. High level analytical and written and oral communication skills are essential.
Back to search results
Atherosclerosis is a leading cause of death worldwide. Current atherosclerosis treatments lower plasma low density lipoprotein cholesterol (LDL-C) levels. However, as optimal LDL-C levels are not always achieved, and residual risk is often present even when very low LDL-C levels are achieved, it is clear that new therapeutic approaches are needed. We have developed a novel peptide, C-II-a, that fills this gap. Preliminary in vitro experiments show that C-II-a is cardioprotective. The project will use state-of-the art molecular and imaging approaches to establish that C-II-a reduces atherosclerosis in animals, and improves human atherosclerotic lesion composition and stability.
University of Sydney
Anzac Research Institute/Concord Hospital